

# Giulia Morsica

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9522941/publications.pdf>

Version: 2024-02-01

52  
papers

856  
citations

686830

13  
h-index

500791

28  
g-index

52  
all docs

52  
docs citations

52  
times ranked

1263  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study. <i>Hepatology</i> , 2006, 43, 556-562.  | 3.6 | 216       |
| 2  | Occult hepatitis B virus infection in a Cohort of HIV-positive patients: Correlation with hepatitis C virus coinfection, virological and immunological features. <i>Infection</i> , 2009, 37, 445-449.   | 2.3 | 56        |
| 3  | Polymerase chain reaction for <i>Toxoplasma gondii</i> DNA in the cerebrospinal fluid of AIDS patients with focal brain lesions. <i>Aids</i> , 1994, 8, 1691-1694.   | 1.0 | 54        |
| 4  | Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV-infected patients. , 1997, 53, 252-254.   |     | 42        |
| 5  | Pretreatment of Chronic Active Hepatitis C in Patients Coinfected With HIV and Hepatitis C Virus Reduces the Hepatotoxicity Associated With Subsequent Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 146-152.  | 0.9 | 40        |
| 6  | Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. <i>Drugs</i> , 2017, 77, 1043-1055.  | 4.9 | 40        |
| 7  | Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. <i>Aids</i> , 2000, 14, 1656-1658.   | 1.0 | 38        |
| 8  | Detection of Hepatitis C Mutants With Natural Resistance to NS3/4A Protease Inhibitors in HIV/HCV-Coinfected Individuals Treated With Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 106-108.   | 0.9 | 28        |
| 9  | Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients. <i>Aids</i> , 2005, 19, S151-S165.  | 1.0 | 27        |
| 10 | Viral Interference Between Hepatitis B, C, and D Viruses in Dual and Triple Infections in HIV-Positive Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 574-581.  | 0.9 | 23        |
| 11 | Design and Characterization of a Peptide Mimotope of the HIV-1 gp120 Bridging Sheet. <i>International Journal of Molecular Sciences</i> , 2012, 13, 5674-5699.   | 1.8 | 22        |
| 12 | A liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1120, 1-7. | 1.2 | 22        |
| 13 | Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment. <i>Viruses</i> , 2016, 8, 91.  | 1.5 | 20        |
| 14 | Prevalence of wild-type in NS5A-PKR protein kinase binding domain in HCV-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2002, 36, 116-122.   | 1.8 | 16        |
| 15 | GB Virus C and Hepatitis C Virus Infection in Patients with Mixed Cryoglobulinemia. <i>Annals of Internal Medicine</i> , 2000, 133, 394.   | 2.0 | 15        |
| 16 | Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: Possible protective effect of infecting HCV genotype on HIV disease progression. <i>Journal of Clinical Virology</i> , 2007, 39, 82-86.   | 1.6 | 13        |
| 17 | Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption. <i>Infection</i> , 2010, 38, 417-421.   | 2.3 | 13        |
| 18 | Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption. <i>Infection</i> , 2011, 39, 121-126.   | 2.3 | 12        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Resistance analysis and treatment outcomes in hepatitis C virus genotype 3a infected patients within the Italian network VIRONET. <i>Liver International</i> , 2021, 41, 1802-1814.  | 1.9 | 12        |
| 20 | Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission. <i>Journal of Medical Virology</i> , 2001, 64, 476-481.  | 2.5 | 11        |
| 21 | Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study. <i>PLoS ONE</i> , 2017, 12, e0184128.                      | 1.1 | 11        |
| 22 | Non-invasive fibrosis biomarkers "APRI" and "Forns" are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs. <i>Liver International</i> , 2013, 33, 1113-1120.                               | 1.9 | 10        |
| 23 | Molecular epidemiology of HIV-1 infection in immigrant population in northern Italy. <i>Epidemiology and Infection</i> , 2020, 148, e19.   | 1.0 | 10        |
| 24 | Virological pattern of hepatitis B infection in an HIV-positive man with fatal fulminant hepatitis B: a case report. <i>Journal of Medical Case Reports</i> , 2009, 3, 110.  | 0.4 | 9         |
| 25 | Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions. <i>Viruses</i> , 2019, 11, 148.   | 1.5 | 9         |
| 26 | Evolution of hepatitis C virus non-structural 5A gene in the progression of liver disease to hepatocellular carcinoma. <i>Liver International</i> , 2007, 27, 1126-1133.   | 1.9 | 8         |
| 27 | Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin. <i>Medicine (United States)</i> , 2015, 94, e1876.   | 0.4 | 8         |
| 28 | Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020, 14, 362-372.  | 1.9 | 8         |
| 29 | HIV-1 recombinant forms in immigrants regularly residing in Milan, northern Italy. <i>Infection</i> , 2020, 48, 553-558.   | 2.3 | 8         |
| 30 | Effect of increasing dose of interferon on the evolution of hepatitis C virus 1b quasispecies. , 2000, 60, 133-138.  |     | 7         |
| 31 | Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2017, 67, 415-417.  | 1.8 | 7         |
| 32 | Hepatitis C virus infection in blood donors with indeterminate results in second-generation recombinant immunoblot assay. <i>Transfusion</i> , 1994, 34, 555-556.  | 0.8 | 6         |
| 33 | NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B. <i>Archives of Virology</i> , 2017, 162, 2271-2277.                               | 0.9 | 6         |
| 34 | Brief Report: Outcome of Acute Hepatitis B Virus Infection in HIV-1 Infected Patients: Possible Factors Associated With Resolution or Chronicity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 175-180. | 0.9 | 6         |
| 35 | Natural polymorphisms in the resistance associated sites of HCV-G1 NS5B domain and correlation with geographic origin of HCV isolates. <i>Virology Journal</i> , 2018, 15, 144.  | 1.4 | 4         |
| 36 | Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfecting and HIV monoinfected patients. <i>New Microbiologica</i> , 2011, 34, 317-21.  | 0.1 | 4         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome. <i>Viruses</i> , 2020, 12, 269.   | 1.5 | 3         |
| 38 | Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naïve individuals infected with hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1448-1450.                                      | 1.3 | 2         |
| 39 | Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman. <i>International Journal of Infectious Diseases</i> , 2014, 29, 100-102. | 1.5 | 2         |
| 40 | Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021, 53, 1603-1609.   | 0.4 | 2         |
| 41 | Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort. <i>Antiviral Therapy</i> , 2020, 25, 73-81.  | 0.6 | 2         |
| 42 | Levels of Alpha-Fetoprotein and Association with Mortality in Hepatocellular Carcinoma of HIV-1-Infected Patients. <i>Journal of Oncology</i> , 2022, 2022, 1-10.  | 0.6 | 2         |
| 43 | Compartmentalization of Resistance-Associated Substitutions in HIV/HCV-Infected Patients: Possible Correlation with Infecting HCV Genotype. <i>Viruses</i> , 2021, 13, 1486.   | 1.5 | 1         |
| 44 | Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV. <i>PLoS ONE</i> , 2022, 17, e0262917.   | 1.1 | 1         |
| 45 | Prevalence of wild-type in interferon sensitivity determining region (ISDR) of hepatitis C virus in HIV-1 positive patients infected with HCV genotype 3A non responders to anti-HCV treatment. <i>Journal of Hepatology</i> , 2002, 36, 71.                             | 1.8 | 0         |
| 46 | Prevalence of a 660 amino acid substitution in the PePHD region of HCV-E2 protein in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2002, 36, 80.  | 1.8 | 0         |
| 47 | HBV/HCV coinfection: viral genomic profile of dominant virus. <i>Journal of Hepatology</i> , 2002, 36, 222.  | 1.8 | 0         |
| 48 | Comparison of IFN- $\alpha$ 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a. <i>Aids</i> , 2004, 18, 1080-1082.   | 1.0 | 0         |
| 49 | The appropriate method of evaluating the dynamics of hepatitis B virus in patients receiving antiviral treatment: the other side of the coin. <i>Aids</i> , 2005, 19, 1933-1934.   | 1.0 | 0         |
| 50 | THU-117-Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naïve to direct acting antivirals: Particular focus on natural resistance. <i>Journal of Hepatology</i> , 2019, 70, e209-e210.               | 1.8 | 0         |
| 51 | SAT-404-Discordant NS5a but not NS3 RASs profile in liver and plasma compartments of HIV/HCV genotype 1a/4d infected patients. <i>Journal of Hepatology</i> , 2019, 70, e812.  | 1.8 | 0         |
| 52 | Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors. <i>New Microbiologica</i> , 2017, 40, 53-55.   | 0.1 | 0         |